Symbols

Symbols

Aime

Products

News

Markets

Watchlist

Brokers

News/

Stock/

IMNN

IMNN News

Newswire

07:48

IMUNON Reports Q3 R&D Day Progress, $24.6mln in Revenue

06:30

Imunon shares surge 11.14% premarket amid R&D day highlights on Phase 3 ovarian cancer trial progress and innovation.

17:12

Imunon Presents OVATION 3 Ovarian Cancer Study Data: IMNN-001 Immunotherapy Progress and Milestones

07:36

IMUNON Presents Ovarian Cancer Treatment Update and Phase 3 Trial Progress

07:31

IMUNON's R&D Day Highlights Positive Ovarian Cancer Treatment Progress and Potential Landmark Breakthrough with IMNN-001

View More

About IMNN

Charts

--

Sector--

Established Date--

Listing Date--

Exchange--

Full-time Employees--

Fiscal Year Ends--

Website

Security Type--

Office address

Business

Introduction

View More